154 related articles for article (PubMed ID: 15106201)
1. Platinum containing regimens for metastatic breast cancer.
Carrick S; Ghersi D; Wilcken N; Simes J
Cochrane Database Syst Rev; 2004; (2):CD003374. PubMed ID: 15106201
[TBL] [Abstract][Full Text] [Related]
2. Platinum containing regimens for metastatic breast cancer.
Carrick S; Ghersi D; Wilcken N; Simes J
Cochrane Database Syst Rev; 2004; (3):CD003374. PubMed ID: 15266482
[TBL] [Abstract][Full Text] [Related]
3. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
4. Single agent versus combination chemotherapy for metastatic breast cancer.
Carrick S; Parker S; Wilcken N; Ghersi D; Marzo M; Simes J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003372. PubMed ID: 15846660
[TBL] [Abstract][Full Text] [Related]
5. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2003; (3):CD003366. PubMed ID: 12917963
[TBL] [Abstract][Full Text] [Related]
6. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2005 Apr; (2):CD003366. PubMed ID: 15846659
[TBL] [Abstract][Full Text] [Related]
7. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.
Jones D; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2006 Jul; (3):CD003368. PubMed ID: 16856005
[TBL] [Abstract][Full Text] [Related]
8. Platinum-containing regimens for triple-negative metastatic breast cancer.
Egger SJ; Chan MMK; Luo Q; Wilcken N
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
[TBL] [Abstract][Full Text] [Related]
9. Antitumour antibiotic containing regimens for metastatic breast cancer.
Lord S; Ghersi D; Gattellari M; Wortley S; Wilcken N; Simes J
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD003367. PubMed ID: 15495049
[TBL] [Abstract][Full Text] [Related]
10. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
12. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
13. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Hind D; Wyld L; Beverley CB; Reed MW
Cochrane Database Syst Rev; 2006 Jan; (1):CD004272. PubMed ID: 16437480
[TBL] [Abstract][Full Text] [Related]
14. Combination versus sequential single agent chemotherapy for metastatic breast cancer.
Dear RF; McGeechan K; Jenkins MC; Barratt A; Tattersall MH; Wilcken N
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008792. PubMed ID: 24347031
[TBL] [Abstract][Full Text] [Related]
15. Single agent versus combination chemotherapy for metastatic breast cancer.
Carrick S; Parker S; Thornton CE; Ghersi D; Simes J; Wilcken N
Cochrane Database Syst Rev; 2009 Apr; 2009(2):CD003372. PubMed ID: 19370586
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer.
Wilcken N; Hornbuckle J; Ghersi D
Cochrane Database Syst Rev; 2003; 2003(2):CD002747. PubMed ID: 12804433
[TBL] [Abstract][Full Text] [Related]
17. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.
Butters DJ; Ghersi D; Wilcken N; Kirk SJ; Mallon PT
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD003368. PubMed ID: 21069675
[TBL] [Abstract][Full Text] [Related]
18. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of taxane-containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes RJ
Br J Cancer; 2005 Aug; 93(3):293-301. PubMed ID: 16052223
[TBL] [Abstract][Full Text] [Related]
20. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
Amarasena IU; Walters JA; Wood-Baker R; Fong K
Cochrane Database Syst Rev; 2008 Oct; (4):CD006849. PubMed ID: 18843733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
